Key result
Heparin products cause self-resolving haemorrhagic bullous dermatosis at ~8 days, disproportionately affecting men.
Answers are grounded in this paper and cite their sources.
Case review reveals spontaneous resolution of heparin-induced haemorrhagic bullous dermatosis in affected patients, suggesting anticoagulation continuation is safe.
BACKGROUND: Heparin-induced haemorrhagic bullous dermatosis (HBD) is a rare but probably underdiagnosed reaction to heparin, with 26 cases reported in the English literature. Currently, there is no consensus regarding the treatment. AIM: To assess our new cases of HBD and review the previously reported cases, in order to draw conclusions about this adverse skin reaction to heparin. METHODS: A PubMed search was performed for articles containing the terms '(heparin-induced AND (blister OR bulla OR bullae)) OR (hemorrhagic bullous dermatosis AND heparin) OR heparin bullous dermatosis'. Descriptive statistical data analysis was performed using Microsoft Excel. RESULTS: We assessed five new cases of HBD. In addition, our literature search revealed 26 previously reported patients. Combining these, we found that the mean ± SD age of patients with HBD was 71.4 ± 14 years. HBD affects men more commonly than women (men 22/31; P = 0.02). Patients develop tense bullae most frequently on the extremities, approximately 8 days (mean ± SD 7.5 ± 6.4 days) after starting treatment with a heparin product, usually enoxaparin. CONCLUSIONS: The typical clinical course is spontaneous resolution within days to weeks irrespective of continuation of heparin therapy. Because of its self-limiting nature, interruption of heparin therapy may not be required.
No takes yet. Share an insight, caveat, or question.
Snow et al. (2017) conducted a review in Heparin-induced haemorrhagic bullous dermatosis (n=31). Heparin product (usually enoxaparin) was evaluated on Clinical characteristics and time to onset of tense bullae (p=0.02). Heparin products caused haemorrhagic bullous dermatosis at a mean of 7.5 ± 6.4 days after treatment initiation, affecting men more commonly than women with spontaneous resolution.
Synapse has enriched 10 related papers. Consider them for comparative context: